DXCM Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action Lawsuit

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly misleading investors regarding its sales force expansion strategy and its impact on customer growth and market share [1][2]. Group 1: Allegations Against DexCom - The lawsuit claims that DexCom's sales force expansion strategy led to slow customer growth [2] - It is alleged that this strategy undermined relationships with durable medical equipment (DME) distributors, which are crucial for revenue generation [2] - The deteriorating relationships with DME distributors reportedly caused DexCom to lose significant market share to competitors [2] - As a result of these issues, statements made by DexCom during the Class Period about its business and operations were deemed false and misleading [2] Group 2: Lead Plaintiff Process - Investors in DexCom have until October 21, 2024, to seek appointment as a lead plaintiff representative in the class action [3] - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3] - The lead plaintiff selects counsel to represent the class, and this decision does not affect the ability of other investors to share in any recovery [3] Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages affected investors to contact them for more information [4][5] - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5]